Srivali Narat, Thongprayoon Charat, Cheungpasitporn Wisit, Ungprasert Patompong
Department of Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, USA.
Department of Medicine, Mayo Clinic, Rochester, MN, USA.
J Basic Clin Pharm. 2015 Jun;6(3):101-2. doi: 10.4103/0976-0105.160753.
Canagliflozin (Invokana) is an innovative treatment for type 2 diabetes mellitus (DM) approved in a new class acknowledged as sodium-glucose co-transporter 2 inhibitors. Acute pancreatitis is a very rare side effect with an incidence <1%. a 50-year-old white male with DM type 2 presented to the emergency department with acute onset of abdominal pain after 4 days treatment with canagliflozin. He was successfully diagnosed with diabetic ketoacidosis induced by acute pancreatitis. Canagliflozin was discontinued. His diabetic ketoacidosis was improved after aggressive intravenous fluid along with intravenous insulin infusion. Our case demonstrates very rare but serious side effect, acute pancreatitis in the use of canagliflozin. As the utility of canagliflozin expands, physicians must be aware of this potentially fatal adverse effect. More specific details on potential candidates for this novel therapy are urgently needed.
卡格列净（怡可安）是一种用于治疗2型糖尿病（DM）的创新疗法，已被批准归入一类新的药物，即钠-葡萄糖协同转运蛋白2抑制剂。急性胰腺炎是一种非常罕见的副作用，发生率<1%。一名50岁的白人男性2型糖尿病患者在接受卡格列净治疗4天后因突发腹痛就诊于急诊科。他被成功诊断为由急性胰腺炎诱发的糖尿病酮症酸中毒。停用了卡格列净。在积极静脉补液并静脉输注胰岛素后，他的糖尿病酮症酸中毒得到改善。我们的病例显示了使用卡格列净时非常罕见但严重的副作用——急性胰腺炎。随着卡格列净的应用范围扩大，医生必须意识到这种潜在的致命不良反应。迫切需要关于这种新型疗法潜在适用患者的更具体细节。
